# OnCo record paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020" ;
  schema:name "Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC"@en ;
  schema:description "In the patients whose tumours showed the most PD-L1, immunotherapy alone gave a median survival of 20.2 months against 13.1 on chemotherapy, with far fewer severe side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1917346>, <https://pubmed.ncbi.nlm.nih.gov/32997907/>, <https://clinicaltrials.gov/study/NCT02409342> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1917346> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Herbst RS, Giaccone G, de Marinis F, et al." ;
  onco:related <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-042-lancet-2019/>, <https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ihc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/terms/immune-checkpoint/> ;
  onco:terms <https://onco.cc/targets/pdl1/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/tmb/> ;
  onco:people <https://onco.cc/people/roy-herbst/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .